Loading...
ORIC logo

ORIC Pharmaceuticals, Inc.NasdaqGS:ORIC Rapport sur les actions

Capitalisation boursière US$843.7m
Prix de l'action
US$8.15
US$20.36
60.0% sous-évalué décote intrinsèque
1Y72.3%
7D-7.9%
Valeur du portefeuille
​
Voir

ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC Rapport sur les actions

Capitalisation boursière : US$843.7m

ORIC Pharmaceuticals (ORIC) Aperçu de l'action

ORIC Pharmaceuticals, Inc. est une société biopharmaceutique en phase clinique qui se consacre à la découverte et au développement de thérapies visant à contrer les mécanismes de résistance dans les cancers aux États-Unis. Plus de détails

ORIC analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées0/6
Santé financière6/6
Dividendes0/6

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Cours de l'action très volatil au cours des 3 derniers mois par rapport au marché US

Réalise moins d'un million de dollars de revenus ( $0 )

Les bénéfices devraient diminuer en moyenne de 8.8% par an au cours des 3 prochaines années

+ 1 plus de risques

ORIC Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

ORIC Pharmaceuticals, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 ORIC Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'actionUS$8.15
Plus haut sur 52 semainesUS$14.93
Plus bas sur 52 semainesUS$4.65
Bêta1.1
Variation sur 1 mois-24.19%
Variation sur 3 mois-18.42%
Variation sur 1 an72.30%
Variation sur 3 ans64.31%
Variation sur 5 ans-67.40%
Évolution depuis l'introduction en bourse-68.37%

Nouvelles et mises à jour récentes

Recent updates

Seeking Alpha • Jan 20

ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

Summary ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity raise, secures operations and Phase 3 trial funding into the second half of 2028. Rinzimetostat and enozertinib have shown promising efficacy and safety in early trials, with both candidates entering registrational Phase 3 studies by 2026. Risks include small Phase 1b sample sizes and intense competition, but ORIC's strategic focus and financial flexibility create an attractive risk/reward profile. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans

Summary ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for now but will need additional funding by late 2025 to support phase 3 trials. The company's valuation is high relative to its early-stage peers, but recent share price declines make it a "Hold" rather than a "Sell". Given the high risk and early data, I recommend a "Hold" rating unless you're highly risk-tolerant; the potential is strong but uncertain. Read the full article on Seeking Alpha
Article d’analyse • Mar 27

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 02

ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data

Summary ORIC Pharmaceuticals' ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. ORIC-114 shows strong CNS penetration and promising results in brain metastasized NSCLC, with a significant market potential. ORIC-944, targeting prostate cancer, has shown encouraging efficacy and big pharma interest, but more data is needed. Despite promising early-stage data, ORIC remains in the high-risk phase 1 stage; more mature data is needed before committing. Read the full article on Seeking Alpha
Article d’analyse • Dec 12

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d’analyse • Aug 21

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 29

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Summary ORIC Pharmaceuticals is developing agents to address resistance to approved cancer therapies, trading at a premium due to recent announcements. The pipeline includes ORIC-114 targeting EGFR/HER2 mutations, ORIC-944 for prostate cancer, and ORIC-533 for multiple myeloma. Financially stable with a long cash runway, but early efficacy data and hype surrounding ORIC stock warrant caution in investing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 17

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Summary ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients. Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively. The company had cash of $331.5 million as of March 31st of 2024; Enough cash to fund its operations into late 2026. Read the full article on Seeking Alpha
Article d’analyse • May 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 13

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Summary ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533. ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first half of 2024 and provide a program update in mid-2024. The global prostate cancer market size is projected to surpass $27.51 billion by 2032. ORIC had $235 million in cash as of December 31st, 2023. It believes that it has enough cash on hand to fund its operations into 2026. Read the full article on Seeking Alpha
Article d’analyse • Jan 18

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Sep 27

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Jun 14

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Jan 24

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ORIC is well-capitalized with Q2 cash position of $237.8M and valuation appears overly pessimistic at EV of negative $80M. ORIC is a Speculative Buy. Key risks include disappointing data for phase 1 readouts 1H 23, delays in the clinic and heavy competition in certain areas. Shares of ORIC Pharmaceuticals (ORIC) have fallen by over 80% since upsized IPO was priced at $16 in April of 2020. So far in 2022, share price has also experienced a dismal 80% decline. Back in March I sold my remaining shares for a 68% loss at $4.50 (still 50% higher than where they currently trade). However, I did highlight conviction-sized insider buying and reminded readers that I planned to revisit in a couple quarters when 2023 readouts were closer. As time has passed, I decided to check back in on the story and found the valuation to be incredibly pessimistic ($120M market capitalization versus estimated Q3 cash position of just over $200M). In other words, Mr. Market is stating that ORIC, with 3 clinical-stage programs in early phase 1b studies, is worth NEGATIVE $80M. These are not merely "me-too" assets, as their EGFR/HER2 exon-20 program is brain penetrant (can address CNS-metastases where approved agents lack activity). Likewise, the PRC2 program is targeting the EED subunit whereas predecessors have opted for the EZH2 subunit (plagued by tolerability issues) and management noted that certain subpopulations in prostate cancer could allow for accelerated approval should data warrant. The above to say, with the usual caveats, that I think we should dig deeper as the company would seem to be worth more than NEGATIVE $80M. Chart Finviz Figure 1: ORIC weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, the decline from highs above $40 to current $3 share price is quite sickening (appears as if the company has "flat-lined" and is a shell of its former self). Despite looking like a shell company, there is still a lot going on under the hood (three phase 1 studies with readouts coming 1H 23) and so my initial suggestion for risk-tolerant investors would be to accumulate a small to modestly sized position at current levels ahead of these events. Given the current macro environment and headwinds to both risk assets as well as biotech sector, purchases could be spaced out over a period of months (or even quarters) instead of all at once. Overview Founded in 2014 with headquarters in San Francisco (78 employees), ORIC Pharma currently sports enterprise value of ~NEGATIVE $80M and estimated Q3 cash position of $200M providing them operational runway into 2H 2024. Here are my notes from September's Wainwright webcast which provides an excellent overview of current operations: ORIC= Overcoming Resistance in Cancer and encompasses their mission statement. Pipeline is broad and consists of potential first-in-class drug candidates and they have 3 ongoing phase 1b single-agent studies focused on validated targets followed by a pipeline of preclinical programs (both internally sourced as well as via external business development). They ended Q2 with $238M in cash with expected operational runway into 2H 24 (over a year after 3 data readouts expected in the first half of 2023). Corporate website Figure 2: Pipeline (Source: corporate website) Leadership team is highly experienced, starting with preclinical research discovery capabilities led by CSO and team that previously worked together at Genentech. They also possess full development, clinical and regulatory capabilities led by CMO and team that worked together previously at Ignyta and Aragon. Finally, they have extensive business development and strategic inlicensing capabilities via a team that worked together previously at Medivation and Ignyta. Successful oncology business models of the past several years tended to focus on building pipeline via internal discovery efforts or via business development. However, ORIC has been able to take a "source agnostic" approach to building the pipeline where the best molecule wins (whether internally developed or externally sourced). ORIC-533 is an oral bioavailable CD73 inhibitor discovered internally, whereas ORIC-114 was sourced from South Korean company Voronoi in October of 2020 and ORIC-944 from Mirati Therapeutics in July of 2020. They have 3 ongoing phase 1b studies. Bar is set high for differentiation versus competitors. Lastly, newest program is first-in-class PLK4 inhibitor in lead optimization stage. Starting with ORIC-533, they believe the molecule is differentiated on two fronts (both preclinically as well as via clinical development plan as a single agent in multiple myeloma). Preclinically versus other small and large molecule inhibitors of CD73 (as well as A2A receptor programs), ORIC-533 showed higher potency in multiple models. Also, 533 differentiates in a high adenosine or high AMP environment as well (important given high levels of adenosine typically seen in tumor microenvironment). For multiple myeloma, last year they showed a variety of preclinical results supporting potential as a single agent followed by combination trials pending single agent activity. Key takeaway from data presented last year (ex vivo autologous patient level) was that ORIC-533 achieved 40% lysis in these models (compared favorably to other approved agents in same models like lenalidomide and bortezomib). In the current phase 1 study they are enrolling late-line MM patients (triple and quad-refractory) starting as single agent. If there is even modest activity (sounds like the bar is not being set high), they'd move into multiple combination cohorts. As far as they know, ORIC-533 is the only CD73 inhibitor being tested as a single agent in multiple myeloma. Wainwright webcast Figure 3: Activity of ORIC-533 in MM comparable to standard of care therapies (Source: Wainwright presentation) Moving on to ORIC-114, this is a brain-penetrant EGFR/HER2 exon-20 program. Management prioritized finding a molecule selective for exon-20 insertion mutations over wild type (been a challenge for other players in the field). Second, they wanted to see CNS activity given prevalence of CNS metastases in this population. This molecule was specifically optimized across selectivity and brain penetration (exquisitely clean). Two currently approved agents for exon-20 have tolerability issues as well as lack of CNS activity. For ORIC-144, potent tumor regression has been observed in multiple non small cell lung cancer EGFR insertion models without significant weight loss. Head-to-head preclinical studies were also performed and 144 compared favorably in terms of efficacy and selectivity/signs of potential toxicities. Wainwright webcast Figure 4: In vivo efficacy for ORIC-144 compares favorably to competitors (Source: Wainwright presentation) The most important thing to highlight is CNS activity, as leading agents don't address CNS mets (35% to 40% of these patients develop CNS mets). In vivo data versus TAK-788 and osimertinib (clinically active CNS compound) showed superiority for ORIC-144. HER2 is another indication of interest for ORIC-144, and benchmark data versus Seagen's (SGEN) HER2 inhibitor tucatinib demonstrated antitumor activity in intracranial HER2+ breast cancer model (outperforming tucatinib). This is important as 50% of HER2+ breast cancer patients develop brain metastases. Phase 1b study is enrolling patients with advanced solid tumors who have either EGFR or HER2 exon-20 alterations or HER2 amplification or overexpression. Unlike competitor phase 1 studies, they are allowing patients with active CNS mets (treated or untreated but asymptomatic). CEO notes that amivantamab from JNJ is a great drug, but the big difference is again they are a large molecule and excluding patients with CNS mets. Wainwright webcast Figure 5: Superior efficacy for ORIC-144 in intracranial EGFR mutant models (Source: Wainwright presentation) Lastly, for allosteric PRC2 inhibitor ORIC-944, CEO notes that the PRC2 complex is a validated target with approved agents for epithelial sarcoma and follicular lymphoma. There are two druggable subunits for this complex, with most companies approaching it via EZH2 (associated with poor tolerability or PK limitations). There is only one other EED inhibitor in oncology (MAK683 from Novartis). Work done by Mirati comparing ORIC-944 to tazmetostat in DLBCL shows the former outperforming the latter by a wide margin. In androgen-resistant prostate cancer models, ORIC-944 showed good tumor growth inhibition (79% to 86% whereas competitors have seen 40% to 45% TGI). Per CEO, phase 1 study is progressing well (enrolling metastatic prostate cancer patients that have failed one or more AR modulators and up to 2 bouts of chemotherapy). These are later line patients lacking great options available, and goal is looking at safety, PK and selection of recommended phase 2 dose (sounds like they are expecting less in terms of early activity). Interestingly, they aim to see subsets of patients or potential biomarkers that would allow for accelerated approval in certain (smaller but still sizeable) populations. Wainwright webcast Figure 6: Strong single agent activity observed for ORIC-944, significantly better than blockbuster drug enzalutamide (Source: Wainwright presentation) PLK4 inhibitor program is in lead optimization, with the rationale being that cells with TRIM37 amplification require PLK4 function for growth and survival. TRIM37 amplification occurs in 20% of breast cancer and 50% of neuroblastoma and has been associated with early relapse and poor prognosis. This represents a synthetic lethality approach. Other Information For the second quarter of 2022, the company reported cash and equivalents of $237.8M contrasting favorably to R&D expenses of $13.8M and G&A expenses of $6.9M. Management is guiding for operational runway into 2H 2024, which seems reasonable to my eyes. Accumulated deficit to date per 10-K filing is around $245M, a reasonable figure for a company founded in 2014. As for competition, I do think it's important to keep an eye on Novartis' PRC2 inhibitor MAK683. Per clinical trials gov website, DLBCL seems to be the lead indication on deck for them. However, the study design allows for evaluation in other advanced malignancies such as nasopharyngeal carcinoma ((NPC)), gastric cancer, prostate cancer or other advanced solid tumors for whom no further effective standard treatment is available. Thus, any positive data reported here would likely spark a sympathy move in shares of ORIC as well. ORIC's PRC2 inhibitor to my eyes could be its crown jewel asset out of the 3 drug candidates currently in human studies. As mentioned above, there are certain populations they could potentially pursue accelerated approval via use of biomarkers such as H3K27 trimethylation. In EGFR exon 20, I am most familiar with Cullinan Oncology's (CGEM) CLN-081, which was the recipient of co-develop deal with Taiho Oncology for $275M upfront (allows for 50/50 US share of profits). Contrast the size of the upfront payment alone to ORIC's negative EV. Core Biotech holding Blueprint Medicines (BPMC) also scooped up LNG-451 in 2021 for $250M upfront payment (this drug candidate is highly brain penetrant as well). I imagine that ORIC will have a hard time going up against such larger players including Takeda, but again showing early monotherapy activity in patients with brain metastases would still positively impact share price and sentiment which are at all-time lows. As for ORIC-533, I remain highly skeptical of the inroads they can make in the highly crowded field of multiple myeloma given the impressive efficacy of approved CAR-T treatments not to mention next-generation cell therapy pioneers behind them (see my previous piece on Arcellx). As for institutional investors of note, EcoR1 Capital owns an 8.8% stake and has been adding to its position. String of insider purchases back in Q2 of this year was also encouraging, with CEO Jacob Chacko buying over $2.6M worth of shares.
Article d’analyse • Oct 08

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q2 GAAP EPS of -$0.51 beats by $0.09. Cash, cash equivalents and investments totaled $237.8 million
Article d’analyse • Jun 24

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Mar 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • Nov 23

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Aug 05

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Apr 16

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Jan 01

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Rendement pour les actionnaires

ORICUS BiotechsUS Marché
7D-7.9%-1.6%-0.3%
1Y72.3%34.3%24.0%

Rendement vs Industrie: ORIC a dépassé le secteur US Biotechs qui a rapporté 34.3 % au cours de l'année écoulée.

Rendement vs marché: ORIC a dépassé le marché US qui a rapporté 24 % au cours de l'année écoulée.

Volatilité des prix

Is ORIC's price volatile compared to industry and market?
ORIC volatility
ORIC Average Weekly Movement16.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Cours de l'action stable: Le cours de l'action de ORIC a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de ORIC ( 17% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

FondéeSalariésPDGSite web
2014104Jacob Chackowww.oricpharma.com

ORIC Pharmaceuticals, Inc. est une société biopharmaceutique en phase clinique qui se consacre à la découverte et au développement de thérapies visant à contrer les mécanismes de résistance dans les cancers aux États-Unis. Ses produits candidats en phase clinique comprennent l'enozertinib, anciennement connu sous le nom d'ORIC-114, un inhibiteur irréversible à pénétration cérébrale et biodisponible par voie orale, actuellement en phase 1b, qui cible sélectivement l'exon 20 du récepteur du facteur de croissance épidermique (EGFR) et l'exon 20 du récepteur 2 du facteur de croissance épidermique humain, avec une forte puissance contre les mutations d'insertion de l'exon 20 ; et le rinzimetostat, anciennement connu sous le nom d'ORIC-944, un inhibiteur allostérique du complexe répressif de polycomb 2 pour le cancer de la prostate, actuellement en phase 1b. La société a conclu un accord de collaboration et de fourniture d'essais cliniques avec Bayer pour évaluer ORIC-944 en combinaison avec l'inhibiteur de l'AR Nubeqa ; et un accord de collaboration et de fourniture d'essais cliniques avec Johnson & Johnson pour évaluer ORIC 944 en combinaison avec l'inhibiteur de l'AR Erleada.

ORIC Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de ORIC Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
ORIC statistiques fondamentales
Capitalisation boursièreUS$843.67m
Bénéfices(TTM)-US$135.21m
Recettes(TTM)n/a
0.0x
Ratio P/S
-6.2x
Ratio P/E

Le site ORIC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ORIC compte de résultat (TTM)
RecettesUS$0
Coût des recettesUS$0
Marge bruteUS$0
Autres dépensesUS$135.21m
Les revenus-US$135.21m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-1.31
Marge brute0.00%
Marge bénéficiaire nette0.00%
Ratio dettes/capitaux propres0%

Quelles ont été les performances à long terme de ORIC?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/17 21:15
Cours de l'action en fin de journée2026/05/15 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

ORIC Pharmaceuticals, Inc. est couverte par 20 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc